Understanding the Current Rating
The 'Hold' rating assigned to Venus Remedies Ltd indicates a neutral stance for investors, suggesting that the stock is expected to perform in line with the broader market or sector averages in the near term. This rating reflects a balanced view of the company's prospects, considering both its strengths and areas where caution is warranted. Investors should interpret this as a signal to maintain existing positions rather than aggressively buying or selling the stock at present.
Quality Assessment
As of 27 September 2026, Venus Remedies Ltd holds an average quality grade. The company has demonstrated consistent operational performance, highlighted by a net-debt-free balance sheet, which reduces financial risk and provides flexibility for future investments or expansions. The firm’s operating profit has grown at an impressive annual rate of 56.81%, underscoring robust business momentum. Additionally, the company has declared positive results for seven consecutive quarters, signalling steady earnings growth and operational stability.
Valuation Perspective
The valuation grade for Venus Remedies Ltd is considered fair. Currently, the stock trades at a price-to-book value of 3.4, which is a premium compared to its peers’ historical averages. This premium reflects investor confidence in the company’s growth prospects but also suggests that the stock is not undervalued. The return on equity (ROE) stands at a respectable 15.5%, indicating efficient utilisation of shareholder capital. Despite the premium valuation, the company’s price-to-earnings-to-growth (PEG) ratio is notably low at 0.1, implying that the stock’s price growth is not excessively stretched relative to its earnings growth.
Financial Trend Analysis
The financial trend for Venus Remedies Ltd is very positive. The latest data shows a remarkable 139.27% growth in net profit, with profit before tax excluding other income (PBT less OI) rising by 198.37% to ₹27.42 crores. The company’s profit after tax (PAT) for the quarter reached ₹22.97 crores, reflecting a 139.3% increase. Return on capital employed (ROCE) is at a high of 19.85%, indicating strong capital efficiency. Over the past year, the stock has delivered an extraordinary 276.06% return, significantly outperforming the BSE500 index, which declined by 2.22% during the same period. This market-beating performance highlights the company’s ability to generate shareholder value despite broader market challenges.
Technical Outlook
From a technical standpoint, Venus Remedies Ltd exhibits a mildly bullish trend. The stock has gained 2.68% in the last trading day and 5.03% over the past week, signalling positive short-term momentum. However, the three-month return shows a decline of 14.17%, suggesting some volatility in recent months. The six-month and year-to-date returns remain strong at 89.43% and 117.74%, respectively, reinforcing the stock’s overall upward trajectory. This mixed technical picture supports the 'Hold' rating, as investors may want to monitor price movements closely before making significant portfolio adjustments.
Additional Considerations
Despite its impressive financial performance and market returns, Venus Remedies Ltd remains a microcap stock with limited institutional ownership. Domestic mutual funds currently hold no stake in the company, which may reflect either a cautious stance on valuation or concerns about the company’s scale and liquidity. This lack of institutional backing can contribute to higher volatility and less analyst coverage, factors that investors should weigh carefully.
Here's How the Stock Looks TODAY
As of 27 September 2026, Venus Remedies Ltd continues to demonstrate strong fundamentals and growth potential, balanced by a valuation that demands careful scrutiny. The company’s net-debt-free status and robust profit growth underpin its financial health, while the premium valuation and mixed technical signals suggest a cautious approach. The 'Hold' rating thus encapsulates a prudent view, advising investors to maintain their current holdings and observe how the company navigates upcoming market conditions and sector dynamics.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Investor Implications
For investors, the 'Hold' rating on Venus Remedies Ltd suggests a wait-and-watch approach. The company’s strong financial metrics and market-beating returns are encouraging, but the premium valuation and limited institutional interest warrant caution. Investors already holding the stock may consider maintaining their positions to benefit from ongoing growth, while new investors might prefer to monitor the stock for more attractive entry points or clearer technical signals.
Sector and Market Context
Operating within the Pharmaceuticals & Biotechnology sector, Venus Remedies Ltd’s performance stands out given the sector’s competitive landscape and regulatory challenges. The company’s ability to sustain high growth rates and maintain profitability is a positive indicator of its operational strength. However, the microcap status and relatively low institutional participation highlight the importance of thorough due diligence and risk management when considering exposure to this stock.
Summary
In summary, Venus Remedies Ltd’s current 'Hold' rating by MarketsMOJO, updated on 24 August 2026, reflects a balanced assessment of its quality, valuation, financial trends, and technical outlook as of 27 September 2026. The company’s strong profit growth, net-debt-free position, and impressive returns are tempered by a premium valuation and mixed technical signals. Investors should weigh these factors carefully, maintaining existing holdings while monitoring market developments and company performance for future opportunities.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
